Hunter syndrome
Genzyme Receives Approval to Market Elaprase in Japan
By admin - Posted on October 5th, 2007
October 4, 2007 -- Genzyme Corp. (NASDAQ: GENZ) announced today that it has received approval to market Elaprase® (idursulfase) in Japan for the treatment of Hunter syndrome. Elaprase is an enzyme replacement therapy developed by Shire Human Genetic Therapies Inc., and Genzyme is commercializing the product in Japan and other Asia Pacific countries under an agreement with Shire. Genzyme intends to launch Elaprase this quarter, following reimbursement approval. » read more »
Latest stories
- Colin Powell Endorses Barack Obama for President: Video from this morning's appearance on Meet the Press
- Keating Economics
- Pelosi: The Legislation Has Failed But the Crisis Has Not Gone Away; We Must Work in a Bipartisan Way to Pass New Legislation
- Congressman Hoyer Statement Following Vote on Emergency Economic Stabilization Act
- Senator McCaskill Calls for Greater Accountability on Wall Street
- Senator Bob Casey Statement on Bailout Bill
- Senator Hillary Clinton Calls for Bipartisan Action on Economic Crisis
- Congress Passes Obama, Murkowski, Allen Bill to Ban Dangerous Mercury Exports
- Barack Obama Statement on Financial Plan Breakthrough
- Barack Obama Calls on VA Secretary to Provide Critical Data on Iraq and Afghanistan Veterans to Improve Veterans Services
